Others are used for differentiating benign from malignant neoplasms with cytokeratin 19 (CK19), Hector Battifora mesothelial cell-1 (HBME-1), galectin-3, and CD56 being mostly tested; however, these markers showed variable sensitivity and specificity, necessitating the need for newer, more helpful markers.5 Here, KRT19 is linked to cancer.